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taken on drugs: authorization, appraisal, and medical choice between alternatives. 
The Innovative Medication Initiative was launched the GetReal project to tackle 
this issue. It gathers representatives of more than 14 pharmaceutical companies, 
public institutions such as EMA, HAS, ZIN, NICE and Academic research teams and 
aims at (1) better understanding how evidence of efficacy and effectiveness should 
be considered and reconciled and (2) proposing operational solutions. Objective 
And methOd: We conducted a focused literature review to gain clarity and per-
spective on the concept of EEG: on which historical background it emerged, how it 
is understood and which solutions have been suggested to narrow it. Results: A 
disconnect between outcomes from clinical trials and information needed for clini-
cal practice has been identified in the process of standardization of drugs assess-
ment (Schwartz, 1967), evidence-based medicine (Feinstein, 1997), and knowledge 
dissemination (Lehman, 1995), and called the EEG. Several factors have been identi-
fied to explain it, including characteristics of real-life health care settings (physi-
cian and patient behaviours) and the weak generalizability of clinical trials due to 
their design. The need for a more systematic assessment of effectiveness is now 
widely acknowledged. Adaptive licencing was recently proposed to account of the 
sequential evidence generation on drugs outcome (Eichler, 2011). The EEG can be 
conceptualized as the interaction of drug effect and “real-life” contextual factors 
(Unutzer, 1999). cOnclusiOns: Although the literature on the EEG is extensive, 
the contextual factors that actually impact drug’s outcome in real-life are still to 
be identified. Innovative and integrative study methods and designs are required 
to enable the EEG to be addressed adequately early on in the drug development 
process: this is the next step in the GetReal project.
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Objective: An increased drive towards personalised healthcare and medicine by 
policy-makers, alongside technological advances in medicines and diagnostics, 
is leading to more personalised medicines coming to market. Given that person-
alised medicines differ from traditional medicines in their development, use and 
cost, previously published articles have stated that current health technology 
assessments (HTA) methodologies are not designed to appropriately evaluate 
these technologies. This research was conducted to provide insights on methods 
for evaluating personalised medicines and what modifications to current HTA 
processes would be needed to ensure robust and timely assessment. methOds: 
Qualitative interviews were conducted with five experts in personalised medi-
cine and market access across the UK, US and Germany to discuss the move-
ment towards and benefits of personalised medicines as well as the key metrics 
on which they should be evaluated. These insights, supported with secondary 
research, were used to provide suggestions on the structure and methodology of 
personalised medicine assessments and how current assessment processes would 
need to be altered to accommodate these unique technologies. Results: The key 
areas where personalised medicines would need special consideration in HTAs 
identified were: - Study design: population size, geography, ethnicity - Companion 
diagnostics: cost, logistics - Unmet need: individualised view of perceived benefit 
- Cost effectiveness: costs and outcomes of therapy and companion diagnostic, 
reduction in overall health care costs cOnculsiOn: The key areas identified are 
discussed in further detail, specifically, as to how they could be incorporated into 
current HTA models to effectively assess personalised medicines and how they 
would influence the decision-making process.
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Objectives: Evidence development programs for novel therapeutics must simul-
taneously demonstrate safety, efficacy, clinical significance, economic value and 
effectiveness to meet diverse stakeholder requirements. This is further compli-
cated by variable evidence needs across global markets and resource limitations. 
Understanding how to address all stakeholder perspectives for treatments in oph-
thalmology was accomplished through primary research. methOds: Conducting 
primary research through in-depth phone interviews and advisory board meet-
ings with patient, payer and clinical stakeholders in three ophthalmic conditions: 
chronic, non-infectious posterior uveitis, wet age-related macular degeneration 
and glaucoma provided important insights. Patient research questions focused on 
identifying patient burden and unmet needs. Further research with physicians and 
payers was accomplished through evaluating diverse criteria applied to assessing 
clinical and economic evidence plans. Results: When therapeutic areas lack 
universally accepted clinical guidelines that can be relied upon to guide treat-
ment decisions, payers rely heavily on clinicians to understand current standard 
of care and accepted endpoints. Clinician leaders, interestingly, were not in uni-
versal agreement. Moreover, physicians and payers differed on use of economic 
endpoints and appropriate therapeutic comparators. Physicians differed on the 
endpoints that would be most relevant for demonstrating treatment response 
and how to address the patient burden. Overall, clinicians were more willing to 
consider clinical trial endpoints that differed from those endpoints found in pub-
lished data. Payers preferred to have consistent endpoints to facilitate indirect 
comparisons between treatments. cOnclusiOns: The differing needs of payer 
and clinician stakeholders create additional barriers for development planning 
for novel therapeutics, particularly when published treatment guidelines are not 
available. Manufacturers must consider multi-stakeholder insights across global 
markets in clinical trial design development. 1Santen Pharmaceuticals, Emeryville, 
CA, USA. 2GfK Market Access, Wayland, MA, USA.
1Eli Lilly and Company, Indianapolis, IN, USA, 2Quintiles Innovation, Morrisville, NC, USA, 3Eli 
Lilly Regional Operations GmbH, Vienna, Austria
Many methods are currently available to estimate treatment effects with observa-
tional data. We conducted simulations evaluating some well-established methods 
(regression, propensity weighting, stratification or matching on propensity) as 
well as some newer ideas (tree based methods, local control, entropy balancing, 
prognostic scoring) under several different scenarios including homogeneous and 
heterogeneous treatment effects. Mean square error, bias, coverage probability for 
the overall treatment effect, and prediction accuracy of personalized treatment 
contrast (for scenarios with heterogeneous treatment effect) were assessed. We 
will present some guidelines for estimating treatment effects with observational 
data and strategies that are appropriate with respect to (i) tree-structured treat-
ment models (ii) polynomial outcome model with interactions (iii) presence of 
noise covariates.
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Objectives: The United Nations recently published its most definitive report, 
calling for greater action on climate change. Historically, however, health tech-
nology assessment (HTA) has had a more narrow focus with emphasis on the 
health of patients and health inequalities. Recently some health care decision 
makers have extended the focus to include the environment, e.g. the Swedish 
Government is considering a Green Premium for generic drugs, and the UK NHS 
has CO2 emissions targets. We consider the case for incorporating environmental 
impacts into HTA, and the associated methodological challenges. methOds: We 
reviewed health care decisions where environmental impacts were considered 
- a summary will be provided in the paper. We then convened a workshop with 
key opinion leaders. Results: There are two lines of reasoning for incorporating 
environmental impacts into HTA: 1) Direct impact: changes in the environment 
could affect the health of individuals; and 2) Health decision makers’ objectives are 
broader and are informed by other policy goals, such as the CO2 targets adopted 
by the NHS in the UK. We also identified two types of methodological challenges 
for implementation. First, the nascent evidence base is insufficient to support 
the accurate comparison of the environmental impact of technologies. Second, 
uncertainty about how best to incorporate evidence into HTA. The cost-utility 
analysis approach favoured by many HTA agencies could capture some of the value 
of environmental impacts – in particular, those that generate health impacts. Both 
cost-benefit analysis and multi-criteria decision analysis have potential, having 
both previously been applied to evaluate both health and environmental inter-
ventions, though are less familiar to health care decision makers. cOnclusiOn: 
Further work is needed to track decision makers’ demand for evidence on environ-
mental impacts. Robust methods also are needed for capturing and incorporating 
environmental data as part of HTA as more decision makers begin incorporating 
environmental impacts.
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Objectives: To develop a new method that naturally extends the UK NICE way 
of single-threshold for incremental cost-effectiveness ratio (ICER). It aims to pro-
vide multiple decision criteria for assessing an ICER of expensive health tech-
nologies such as molecular-targeted cancer drugs and regenerative medicine 
products. methOds: We took a theoretical approach, provided that the cost (C) 
-effectiveness (E) function, C = f (E), is known regarding the treatment alternatives 
for a disease area, given two points Pb and Ps plotted with a pair of C and E on the C-E 
plane, where Pb represents the best comparator, and Ps as the second best for a new 
technology X located at the point. Px (ex (effectiveness; known), cx (cost; assumed)). 
At first, given a single threshold of ICER, the “expensiveness” in the C-E function 
was defined using a tangent/derivative method (poster presentation PRM119 by 
Kamae I, et. al. in ISPOR Montreal 2014). Second, we estimated three benchmarks 
based on the C-E function: 1) the ICER of Pb to Ps, 2) the tangent at Pb, 3) the tangent 
at the point on the C-E curve which intersects with the vertical line at the point: 
(E, C) = (ex, 0). Then the magnitude relationship was examined between the three 
benchmarks and the ICER of the technology X defined by the slope of the line con-
necting Px with Pb. Results: Multiple decision criteria at six levels were identified 
and formulated as for acceptance of the “expensive” cost-effectiveness of a new 
health technology: 1) unconditional acceptance (simple dominance), 2) preferred 
(extended dominance), 3) less preferred, 4) minimally preferred, 5) not preferred, 
but negotiable, and 6) cannot accept. Example calculations clarified how the theory 
works in practical setting. cOnclusiOns: Our approach offers multiple decision 
criteria to assess expensive health technologies as a natural extension beyond the 
NICE way of single-threshold assessment.
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bAckgROund: The concept of “efficacy-effectiveness gap” (EEG) has gained aware-
ness in the scientific community and started to erode the confidence in decisions 
